Low EGF in myeloablative allotransplantation: association with severe acute GvHD in BMT CTN 0402.

TitleLow EGF in myeloablative allotransplantation: association with severe acute GvHD in BMT CTN 0402.
Publication TypeJournal Article
Year of Publication2017
AuthorsHoltan, SG, Newell, LF, Cutler, C, Verneris, MR, DeFor, TE, Wu, J, Howard, A, MacMillan, ML, Antin, JH, Blazar, BR, Weisdorf, DJ, Panoskaltsis-Mortari, A
JournalBone Marrow Transplant
Volume52
Issue9
Pagination1300-1303
Date Published2017 Sep
ISSN1476-5365
KeywordsAdult, Bone Marrow Transplantation, Epidermal Growth Factor, Female, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Male, Middle Aged, Transplantation Conditioning, Vascularized Composite Allotransplantation
Abstract

Epidermal growth factor (EGF) is a recently described biomarker of acute GvHD (aGvHD). Whether low plasma EGF prior to hematopoietic cell transplantation (HCT) predisposes to the development of aGvHD, or whether EGF levels fall because of severe aGvHD, is unknown. To evaluate this, we tested plasma samples collected at pre-HCT baseline, day +28 and day +100 during the course of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0402. We found that baseline EGF plasma concentrations were three-fold lower in HCT recipients compared to donors (24.3 vs 76.0 pg/mL, P

DOI10.1038/bmt.2017.89
Alternate JournalBone Marrow Transplant
PubMed ID28581470
PubMed Central IDPMC5699445
Grant ListU10 HL069294 / HL / NHLBI NIH HHS / United States
UG1 HL069290 / HL / NHLBI NIH HHS / United States
P30 CA077598 / CA / NCI NIH HHS / United States
UG1 HL069249 / HL / NHLBI NIH HHS / United States
U24 CA076518 / CA / NCI NIH HHS / United States
R37 AI034495 / AI / NIAID NIH HHS / United States
UG1 HL109137 / HL / NHLBI NIH HHS / United States